Inventiva stock sinks 20% after serious adverse event in NASH trial leads to enrollment pause
Inventiva has paused screening and entering new patients in its Phase III NASH study for lanifibranor after a possibly treatment-related adverse event.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
